Add Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer

Combined-tests-of-prostate-specific-antigen-and-testosterone-will-improve-diagnosis-and-monitoring-the-progression-of-prostate-cancer.md

@@ -0,0 +1,11 @@
+<br>
+<br>It has been believed that a severe reduction of serum androgen levels caused regression of PCa and that increasing androgen levels enhanced PCa growth. A concern for initiating TRT to normalize T levels is that raising serum T levels will increase the risk of PCa incidence and enhance PCa growth. On the basis of these data, clinical studies are suggested to confirm whether PCa patients with low serum PSA level is accompanied with low serum T level.
+These androgen receptor disruptions are found in only up [best place to buy testosterone](http://www.xngel.com/@floylaws37135?page=about) 6% of biopsies of castrate-sensitive metastatic disease. As cells begin to grow out of control, they form a small clump of dysregulated cells called a prostatic intraepithelial neoplasia (PIN). These cells can spread through the lymphatic system to nearby lymph nodes, or through the bloodstream to the bone marrow and (more rarely) other body sites.
+The cells lining this part of the urethra differentiate into the glandular epithelium of the prostate. About 20,000 protein-coding genes are expressed in human cells and almost 75% of these genes are expressed in the normal prostate. Disorders of the prostate include enlargement, inflammation, infection, and cancer. Prostate cancer screening and awareness have been widely promoted since the early 2000s by Prostate Cancer Awareness Month in September and Movember in November. In the 1950s the advent of more powerful radiation machines allowed for external beam radiotherapy to reach the prostate. PSA levels greater than 1 ng/mL are generally considered above normal by gender care specialists. As are single-nucleotide polymorphisms in the vitamin D receptor common in African-Americans, and in the androgen receptor, CYP3A4, and CYP17 involved in [buy testosterone booster](https://git.malls.iformall.com/reedcandler748) synthesis and signaling.
+If cancer is present, the pathologist assigns a Gleason score; a higher score represents a more dangerous tumor. However, significantly elevated PSA levels or rapidly rising PSA levels would warrant further investigation and may preclude TRT until the underlying cause is determined. Monitoring PSA levels during TRT helps to detect any potential issues early on. As discussed, the key issue is the potential to accelerate the growth of existing cancer, not to induce the formation of new cancerous cells. However, because PSA levels increase with age, some doctors apply a higher cutoff (such as 5 ng/ml) for older men and a lower cutoff ( such as 2.5 ng/mL) for younger men (1). In general, a PSA level above 4.0 ng/mL is considered abnormal and may result in a recommendation for prostate biopsy. Most organizations now recommend that individuals who are considering PSA screening first discuss the risks and benefits with their doctors before making a decision.
+TRT doesn’t fix or cure the underlying cause of low [buy testosterone without prescription](http://121.36.47.159:3000/hayleyshoemake/hayley1992/wiki/TESTOSTERONE-GEL-PUMP-2%25-TRANSDERMAL-Fortesta-Uses%2C-Precautions%2C-Side-Effects%2C-Interaction%2C-Warnings). This can help improve the symptoms of low testosterone, like low libido and lack of energy. As of 2025, it’s not yet approved for males who naturally experience a decline in [buy testosterone cream](https://www.jo-line.eu/christenprovos) as they age. For example, chemotherapy or radiation therapy can damage one of these organs. Together, you and your healthcare provider will decide if TRT is right for you.
+Undiagnosed prostate cancer is a significant risk, and TRT could accelerate its progression. Men considering TRT should have open and honest conversations with their doctor about their prostate health and any family history of prostate cancer. A comprehensive evaluation by a medical professional, including prostate cancer screening, is vital to determine if TRT is appropriate. The purpose of this screening is to identify any existing, undiagnosed prostate cancer. Before initiating TRT, men should undergo thorough prostate cancer screening.
+Data of the included studies were not sufficient to evaluate the risk of prostate cancer with [buy testosterone gel online](https://channel-u.tv/@pvyemerson2117?page=about) replacement therapy; however, based on evidence in the literature it does not appear that the risk of prostate cancer is affected by [buy testosterone enanthate](https://code.wemediacn.com/franziskajacke) replacement therapy. Our results show that the serum testosterone level at the time of diagnosis was unrelated to PSA and prostate cancer risk and aggressiveness. In summary, the present study found that the serum [buy testosterone gel online](https://career.ltu.bg/employer/unveiling-the-truth-is-testosterone-a-controlled-substance/) level at the time of diagnosis was unrelated to PSA and prostate cancer risk and aggressiveness. Furthermore, prostate cancer prevalence did not increase as [testosterone online pharmacy](https://bfreetv.com/@niklasespinosa?page=about) levels increased.
+An animal study by Morgentaler and Traish showed that beyond a certain serum [buy testosterone](https://fmagency.co.uk/companies/ignored-by-doctors-trans-people-turn-to-dangerous-underground-treatments/) concentration, androgens have a limited ability to stimulate prostate cancer growth . Long-term cessation of the prostate's exposure to androgen appears to protect against the development of cancer, but no dose-response relationship between testosterone level and cancer risk has been established. Odds ratios with 95% confidence intervals (CIs) for PSA, PSAD, serum testosterone, and age were determined to predict prostate cancer risk. For possible correlation between serum testosterone, PSA, and prostate cancer, we included age, PSA density (PSAD), prostate volume, and Gleason score for patients with prostate cancer. To determine the relationship between testosterone, PSA, and prostate cancer risk in a high-risk group, we limited our study population to men with a PSA level of 10 ng/ml or higher. Isbarn et al's recent studies, however, show a result opposite that of Huggins and Hodges, implying that [testosterone purchase](https://gitea.belanjaparts.com/finnlinderman2) neither increases the risk of prostate cancer nor causes cancer recurrence in men who have been treated successfully for prostate cancer .
+Prostate cancer was initially considered a rare disease, probably because of shorter life expectancies and poorer detection methods in the 19th century. Prostate cancer was first described in a speech to the Medical and Chiurgical Society of London in 1853 by surgeon John Adams and increasingly described by the late 19th century. John E. McNeal first proposed the idea of "zones" in 1968; McNeal found that the relatively homogeneous cut surface of an adult prostate in no way resembled "lobes" and thus led to the description of "zones". The fact that the prostate was one and not two organs was an idea popularised throughout the early 18th century, as was the English language term used to describe the organ,  [git.htns.com](https://git.htns.com/jonahbalog8723/gitea.avixc-nas.myds.me2023/wiki/Blasting-and-cruising%3A-why-%26-how%21) prostate, attributed to William Cheselden. The first time a word similar to prostate was used to describe the gland is credited to André du Laurens in 1600, who described it as a term already in use by anatomists at the time. The prostate was first formally identified by Venetian anatomist Niccolò Massa in Anatomiae libri introductorius (Introduction to Anatomy) in 1536 and illustrated by Flemish anatomist Andreas Vesalius in Tabulae anatomicae sex (six anatomical tables) in 1538.
+<br>